Loading...
The use of erythropoiesis-stimulating agents (ESAs) to treat anemia has been associated with increased risk for thromboembolism (TE) and reduced survival among patients receiving chemotherapy. However, ESAs often reduce the need for blood transfusions, which can cause allergic reactions and transmit infection.
To assist clinicians in assessing the risks and benefits of ESAs in cancer patients, the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) have updated their guidelines on this topic. Evidence came from 5 meta-analyses, 2 systematic reviews, and 13 randomized clinical trials. Key recommendations include the following:
Before starting a patient on an ESA, clinicians should look for potential causes…